NCT02476890View on ClinicalTrials.gov

Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 28, 2015

Primary Completion Date

October 20, 2016

Study Completion Date

October 20, 2016

Conditions
Refractory Chronic Cough
Interventions
DRUG

Gefapixant 100 mg

Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2

DRUG

Placebo

Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02476890 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) | Biotech Hunter | Biotech Hunter